|Articles|December 19, 2017

Flu Vaccine: The Jar Is Three-Quarters Full, Not Half Empty

William Schaffner, MD, explains the strengths and weaknesses of the flu vaccine.

William Schaffner, MD, medical director of the National Foundation for Infectious Diseases, explains the strengths and weaknesses of the flu vaccine.

Interview Transcript (modified slightly for readability):

“Flu vaccine is pretty darn good vaccine; it’s not a perfect vaccine. It’s not like the measles vaccines that will prevent measles completely. We all know that we have to get the vaccine each year because the virus mutates and we have to reformulate the vaccine. And we also know, although it protects many people completely, it may, indeed, result in some people getting influenza despite the vaccine, but it will be a milder infection. So, let’s think about the jar [as] three-quarters full, rather than half empty. Put the accent on the positive salable. We should use this vaccine, which is the best we have available today, to prevent as many illnesses as possible. Who wants to go to the hospital as a patient? Going as a doctor is one thing, but going as a patient? No. Let’s prevent that happening from flu.”


Related to this article

GSK's mRNA Influenza Vaccine Moves to Phase 3 Trial
GSK will advance its investigational mRNA seasonal flu vaccine candidate, which targets both hemagglutinin and neuraminidase, into a phase 3 trial in September 2026 after the shot outperformed licensed flu vaccines in a phase 2 study.
REMAP-CAP and the Tamiflu “Pre-Release”: A Set-Up for Disaster
Preliminary REMAP-CAP data suggesting oseltamivir may increase mortality in critically ill ICU influenza patients has sparked polarized reactions, but clinicians should await the full peer-reviewed manuscript before drawing broad conclusions, since the signal comes from a narrow, severely ill population and may reflect a therapeutic window effect rather than a blanket lack of efficacy.
Asymptomatic C difficile Colonization in Infants Doesn’t Mean Benign
A new study in infants challenges the long-standing belief about the pathogen’s effects in the youngest pediatric population. Senior author Joseph Zackular, PhD, provides insights around his work including how it reshapes gut development and offers potential intervention strategies to shield neonates.
How The Food Safety Surveillance Infrastructure Works in the US
In the first episode of our new series looking at the food safety network, Lynette Johnston, PhD, offers insights into how the federal government surveillance infrastructure operates and how epidemiologists serve as food detectives in determining bacterial pathogens and potential foodborne outbreaks.
New Diagnositics for Legionella Pneumonia May Streamline Care Continuum
Reported cases of Legionnaires’ disease have been on the rise for the past decade, and identifying Legionella bacteria requires specialized testing in the microbiology lab. Here is a clinical overview of Legionella bacteria, including required testing, treatment, and reporting to public health officials.